Related Experiment Videos
The proteasome: a novel target for cancer chemotherapy
1MRC Toxicology Unit, University of Leicester, Leicester, UK.
Abstract:
The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis. The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation. Several proteasome inhibitors exert anti-tumour activity in vivo and potently induce apoptosis in tumour cells in vitro, including those resistant to conventional chemotherapeutic agents. By inhibiting NF-kappaB transcriptional activity, proteasome inhibitors may also prevent angiogenesis and metastasis in vivo and further increase the sensitivity of cancer cells to apoptosis. Proteasome inhibitors also exhibit some level of selective cytotoxicity to cancer cells by preferentially inducing apoptosis in proliferating or transformed cells or by overcoming deficiencies in growth-inhibitory or pro-apoptotic molecules. High expression of oncogene products like c-Myc also makes cancer cells more susceptible to proteasome inhibitor-induced apoptosis. The induction of apoptosis by proteasome inhibitors varies between cell types but often occurs following an initial accumulation of short-lived proteins such as p53, p27, pro-apoptotic Bcl-2 family members or activation of the stress kinase JNK. These initial events often result in a perturbation of mitochondria with concomitant release of cytochrome c and activation of the Apaf-1 containing apoptosome complex. This results in activation of the apical caspase-9 followed by activation of effector caspases-3 and -7, which are responsible for the biochemical and morphological changes associated with apoptosis.
Insights
Proteasome inhibitors show promise as anti-cancer agents by inducing tumor cell apoptosis and inhibiting cancer growth. These compounds offer a novel therapeutic strategy, particularly for drug-resistant cancers.
Area of Science:
- Cell Biology
- Molecular Oncology
- Pharmacology
Background:
- The ubiquitin-proteasome system regulates critical cellular processes like growth and apoptosis.
- Proteasome inhibitors are being investigated as novel anti-cancer therapeutics.
- These inhibitors demonstrate anti-tumor activity and induce apoptosis in cancer cells, including those resistant to chemotherapy.
Purpose of the Study:
- To explore the anti-cancer potential of proteasome inhibitors.
- To understand the mechanisms by which proteasome inhibitors induce apoptosis in cancer cells.
- To evaluate their selective cytotoxicity towards cancer cells.
Main Methods:
- In vitro and in vivo studies of proteasome inhibitor efficacy.
- Analysis of molecular pathways involved in proteasome inhibitor-induced apoptosis, including NF-kappaB, c-Myc, and stress kinases.
- Investigation of mitochondrial pathway activation and caspase cascade signaling.
Main Results:
- Proteasome inhibitors induce apoptosis in various cancer cells, overcoming chemoresistance.
- Inhibition of NF-kappaB by proteasome inhibitors may reduce angiogenesis and metastasis.
- Selective cytotoxicity is observed, with cancer cells showing increased susceptibility due to oncogene expression or deficiencies in regulatory molecules.
- Apoptosis induction involves the accumulation of specific proteins, stress kinase activation, mitochondrial perturbation, and caspase cascade activation.
Conclusions:
- Proteasome inhibitors represent a promising class of anti-cancer drugs with broad applicability.
- Their ability to induce apoptosis through multiple pathways, including selective targeting of cancer cells, highlights their therapeutic potential.
- Further research into proteasome inhibitor mechanisms can optimize their use in cancer treatment.